fda warning letter compounding semaglutide october 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP-1 is FDA-approved, warns – Partnership for Safe Medicines Societies take stand against off-brand
Description
For example, if you started a GLP-1 in September 2024 with a BMI of 37 but in July 2026 youve lost weight and now have a BMI of 34, the prescriber should attest in the prior authorization request that you met the BMI criteria of 35 or over when the GLP-1 therapy started
Frequently Asked Questions (FAQs) Is Retatrutide (10mg) in stock
We adjust dosing based on body weight, insulin response, appetite suppression, and gastric emptying
Li Z, Zhang Y, Meng X, et al
